Designing a double-blind protocol for MK-677 means confronting a compound that makes itself known. Unlike GLP-1 receptor agonists, where nausea and appetite loss can unblind a trial, MK-677 announces itself through hunger. This hunger is not subtle. Published research shows ghrelin mimetics increase food intake by something like 20-30% in controlled settings. A placebo that does not trigger the same drive will be obvious to participants within days.
The problem grows when you consider Medicare's new coverage for obesity treatments. GLP-1 trials had to wrestle with side-effect unblinding for years. Their solutions offer a starting point. But MK-677 is not a GLP-1 drug. It is a growth hormone secretagogue. The hunger it produces is the intended mechanism, not a side effect. That changes everything about how you mask group assignment.
Why does MK-677 unblind itself so quickly?
MK-677 binds the ghrelin receptor directly. Ghrelin is the body's primary hunger signal. When you activate that receptor, the brain receives an unambiguous message: eat. Most people feel this within an hour of dosing. The literature on MK-677 suggests the effect peaks around 2-4 hours after ingestion. A placebo pill cannot replicate this. Even an active placebo that causes mild nausea would not match the specific drive for food.
GLP-1 agonists faced a similar challenge. Their gastrointestinal effects are hard to hide. Trial designers used active run-in periods where all participants received the drug first. Those who could not tolerate it were excluded. This reduced later unblinding because everyone remaining had experienced the side effects. For MK-677, an active run-in might work differently. You would give all participants the real compound for a week. Then randomize. The memory of hunger might carry over into the placebo phase for a short time. But published research on ghrelin shows tolerance to the hunger effect does not develop quickly. The signal would return.
What can we borrow from GLP-1 trial designs?
GLP-1 trials often used a dose-escalation schedule to minimize side effects. For MK-677, you could do the opposite. Start all participants on a low dose that produces mild hunger. Then escalate the treatment group to a higher dose while keeping the placebo group on the low dose. The problem is that MK-677's effects are dose-dependent. A low dose still causes hunger. It is just less intense. The difference between groups might still be detectable.
Another GLP-1 strategy was to measure expectations. Researchers asked participants to guess their group assignment at regular intervals. When guesses were no better than chance, blinding was considered intact. For MK-677, you would need to ask about hunger specifically. If the placebo group reports no change and the treatment group reports marked hunger, blinding has failed. The data from such a trial would be hard to interpret. Any outcome related to body composition or muscle mass would be confounded by the difference in food intake.
Medicare's new coverage for obesity drugs changes the landscape. It means more trials will be funded. It also means regulators will scrutinize blinding more closely. A comparison of MK-677 and GLP-1 agonists shows they act on different appetite pathways. This makes the blinding challenge unique. You cannot simply copy a GLP-1 protocol.
Could an active placebo work for MK-677?
An active placebo is a substance that mimics the side effects of the drug without producing the therapeutic effect. For MK-677, you would need something that causes hunger. The problem is that most hunger-inducing compounds are not benign. You could use a low dose of a different ghrelin receptor agonist. But that would confound the results. You could use a compound that causes hypoglycemia. That would be dangerous and unethical.
Another option is to use a compound that causes a different but equally noticeable sensation. For example, niacin causes flushing. Participants might attribute any unusual feeling to the drug. But hunger is a specific, directional cue. People know when they are hungry. They do not confuse it with a hot flush. The literature on active placebos suggests they work best when the side effects are nonspecific, like drowsiness or dry mouth. Hunger is too targeted.
Some researchers have proposed using a compound like Melanotan II, which can cause nausea and appetite suppression, as a distractor. But that would create a trial comparing two active compounds, not a true placebo-controlled design. It would also introduce safety concerns. Melanotan II has its own risk profile. The FDA would likely reject such a design for a Phase II trial.
How do other peptides handle blinding?
Peptides like Semax and AOD-9604 have been studied in contexts where blinding is less critical. Semax is often used in cognitive research where subjective effects are mild. AOD-9604 is a fragment of growth hormone studied for fat loss. Its effects are not immediately noticeable. That makes blinding easier. MK-677 is different. The hunger is impossible to ignore.
Dihexa presents an even more extreme case. Its effects on cognition might take weeks to manifest. Blinding is straightforward because there is no acute subjective signal. NAD+ precursors also have subtle effects. The challenge with MK-677 is that the primary endpoint, growth hormone secretion, is tied to a sensation that is impossible to mask. You could measure IGF-1 levels as a biomarker. But participants would still know their group assignment. That knowledge could affect their behavior, their diet, their exercise. The trial would measure the effect of knowing you are taking MK-677, not the effect of MK-677 itself.
What about using a crossover design?
A crossover trial would have each participant take both MK-677 and placebo in random order. This design is powerful because each person serves as their own control. But it makes blinding even harder. Once a participant has experienced the hunger from MK-677, they will recognize it in the second phase. The carryover effect would be enormous. You would need a long washout period. But even then, the memory of the sensation would persist.
Some trials use a "double-dummy" design where each participant takes two sets of pills, one active and one placebo, in